...
首页> 外文期刊>Clinical & developmental immunology. >Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
【24h】

Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein

机译:nsp2蛋白中具有32个氨基酸缺失的高致病性PRRSV活疫苗候选者的衰减和免疫原性。

获取原文
获取原文并翻译 | 示例

摘要

A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity study showed that pigs inoculated with QY1P100 and P80 did not develop any significant PRRS clinic symptoms. However, mild-to-moderate clinical signs and acute HP-PRRSV symptoms of infection were observed in pigs inoculated with QY1 P60 and P5, respectively. Furthermore, we determined the whole genome sequences of these four intermediate viruses. The results showed that after 100 passages, compared to QY1 P5, a total of 32 amino acid mutations were found. Moreover, there were one nucleotide deletion and a unique 34-amino acid deletion found at 5'UTR and in nsp2 gene during the attenuation process, respectively. Such deletions were genetically stable in vivo. Following PRRSV experimental challenge, pigs inoculated with a single dose of QY1P100 developed no significant clinic symptoms and well tolerated lethal challenge, while QY1 P80 group still developed mild fever in the clinic trial after challenge. Thus, we concluded that QY1P100 was a promising and highly attenuated PRRSV vaccine candidate.
机译:猪繁殖与呼吸综合症病毒(PRRSV)QY1连续传给Marc-145细胞。确定了QY1不同中间衍生物(P5,P60,P80和P100)的毒性。研究发现,QY1在体外过程中逐渐被衰减。致病性研究表明,接种QY1P100和P80的猪没有出现任何明显的PRRS临床症状。但是,在分别接种QY1 P60和P5的猪中观察到了轻度至中度的临床体征和急性HP-PRRSV感染症状。此外,我们确定了这四种中间病毒的整个基因组序列。结果表明,与QY1 P5相比,经过100次传代后,共发现32个氨基酸突变。此外,在减毒过程中,分别在5'UTR和nsp2基因中发现一个核苷酸缺失和一个独特的34个氨基酸缺失。这样的缺失在体内是遗传稳定的。 PRRSV实验性攻击后,单剂量QY1P100接种的猪没有出现明显的临床症状,并且耐受性极强,即使在挑战后QY1 P80组仍在临床试验中出现轻度发烧。因此,我们得出的结论是,QY1P100是有前途且高度减毒的PRRSV疫苗候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号